About LYFAX
AlphaCentric Life Sciences and Healthcare Fund Class A is a mutual fund dedicated to seeking long-term capital appreciation through investments in the life sciences and healthcare sectors. The fund primarily invests in equity securities of companies involved in pharmaceuticals, medical technology, healthcare equipment, services, and related scientific advancements. Its holdings include major industry players such as AbbVie Inc., Merck & Co. Inc., and AstraZeneca PLC, reflecting broad exposure to both established and innovative organizations within the sector. With a focus on companies that contribute to health preservation, medical research, and technological development, the fund aims to tap into the ongoing growth and evolution of global healthcare markets. Since its inception in late 2019, it has managed a diversified portfolio of approximately 64 holdings, offering investors access to a dynamic and resilient industry characterized by continual demand and regulatory attention. The fund maintains a moderate level of risk, as indicated by a 5-year beta of 0.65, and distributes dividends on a semi-annual basis, making it a noteworthy option for those interested in the healthcare and life sciences landscape.
Fund Family AlphaCentric Funds
Category Health
Performance Rating Average
Risk Rating Above Average
Stock Exchange NASDAQ
Ticker Symbol LYFAX
Share Class Class A
Index S&P 500 TR
LYFAX had a total return of 48.84% in the past year, including dividends. Since the fund's
inception, the average annual return has been 13.83%.
